China Universal Asset Management Co. Ltd. Raises Stock Holdings in Astera Labs, Inc. $ALAB

China Universal Asset Management Co. Ltd. boosted its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 175.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,200 shares of the company’s stock after buying an additional 6,500 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Astera Labs were worth $922,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Astera Labs in the 2nd quarter worth approximately $29,000. Bernard Wealth Management Corp. purchased a new stake in Astera Labs in the second quarter valued at approximately $36,000. Clearstead Trust LLC lifted its stake in Astera Labs by 46,100.0% during the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after purchasing an additional 461 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Astera Labs by 68.6% during the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after purchasing an additional 194 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its position in shares of Astera Labs by 141.5% during the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after buying an additional 283 shares during the period. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Astera Labs Stock Performance

ALAB stock opened at $148.85 on Monday. The company’s 50 day moving average price is $166.62 and its 200 day moving average price is $154.01. The firm has a market capitalization of $25.14 billion, a price-to-earnings ratio of 134.10, a PEG ratio of 2.77 and a beta of 1.52. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.39 by $0.10. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The company had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. During the same quarter in the previous year, the business posted $0.23 EPS. The firm’s revenue was up 103.9% on a year-over-year basis. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Equities analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALAB has been the topic of several research reports. Roth Capital increased their target price on Astera Labs from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Citigroup reiterated an “outperform” rating on shares of Astera Labs in a research note on Tuesday, December 9th. CICC Research initiated coverage on shares of Astera Labs in a research report on Friday, August 29th. They set an “outperform” rating and a $190.00 price target on the stock. Raymond James Financial began coverage on shares of Astera Labs in a report on Friday, November 21st. They issued a “hold” rating for the company. Finally, Northland Capmk upgraded shares of Astera Labs from a “hold” rating to a “strong-buy” rating in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $188.17.

Insider Transactions at Astera Labs

In other news, COO Sanjay Gajendra sold 90,459 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $144.69, for a total transaction of $13,088,512.71. Following the completion of the transaction, the chief operating officer directly owned 1,599,750 shares of the company’s stock, valued at approximately $231,467,827.50. This represents a 5.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Michael Truett Tate sold 11,430 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $144.69, for a total value of $1,653,806.70. Following the completion of the transaction, the chief financial officer owned 192,297 shares in the company, valued at approximately $27,823,452.93. The trade was a 5.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 586,936 shares of company stock valued at $89,331,140 over the last ninety days. Company insiders own 12.50% of the company’s stock.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.